CD8A and neoplasm: Antibody-mediated T cell depletion tests on the BSA-Man@Mn2+-Ft@Lap-treated 4T1-tumor-bearing Balb/c mice showed that the nanoagonist-induced CD8+ T cells are a major contributing factor for the treatment-induced tumor regression, for which the antitumor effects of the nanoagonist was largely abrogated in the antiCD4 and antiCD8 groups without inducing significant alterations in the DC maturation and M1 macrophage polarization levels.